A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®)
Joint Authors
Erdogan, Gurkan
Demir, Gokhan
Yıldız, Burçin Kepez
Eris, Erdem
Perente, Irfan
Aygit, Ebru Demet
Source
Case Reports in Ophthalmological Medicine
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-10-02
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion.
By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
American Psychological Association (APA)
Eris, Erdem& Erdogan, Gurkan& Perente, Irfan& Demir, Gokhan& Yıldız, Burçin Kepez& Aygit, Ebru Demet. 2017. A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®). Case Reports in Ophthalmological Medicine،Vol. 2017, no. 2017, pp.1-3.
https://search.emarefa.net/detail/BIM-1148049
Modern Language Association (MLA)
Eris, Erdem…[et al.]. A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®). Case Reports in Ophthalmological Medicine No. 2017 (2017), pp.1-3.
https://search.emarefa.net/detail/BIM-1148049
American Medical Association (AMA)
Eris, Erdem& Erdogan, Gurkan& Perente, Irfan& Demir, Gokhan& Yıldız, Burçin Kepez& Aygit, Ebru Demet. A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®). Case Reports in Ophthalmological Medicine. 2017. Vol. 2017, no. 2017, pp.1-3.
https://search.emarefa.net/detail/BIM-1148049
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1148049
